Drug Profile

CT 38

Alternative Names: CT38

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cortene
Developer Bateman Horne Center; Cortene
Class Analgesics; Antibacterials; Peptides
Mechanism of Action CRF receptor type 2 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Chronic fatigue syndrome; Encephalomyelitis
No development reported Fibromyalgia; Lyme disease

Most Recent Events

28 Mar 2024 No recent reports of development identified for phase-I development in Fibromyalgia in Unknown
28 Mar 2024 No recent reports of development identified for phase-I development in Lyme-disease in Unknown
02 Sep 2021 Preliminary efficacy and adverse event data from the phase I/II InTiME trial in Encephalomyelitis and Chronic fatigue syndrome released by Cortene

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com